Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hydroxamic acid group-containing diarylethene LSD1/HDACs double-target inhibitors as well as preparation method and application thereof

A technology of diarylethene and hydroxamic acid is applied in the field of application of diarylethene LSD1/HDACs dual-target inhibitors to prepare antitumor drugs, and achieves good selectivity, is conducive to popularization and application, and has good in vitro performance. The effect of antitumor activity

Active Publication Date: 2020-08-28
XINXIANG MEDICAL UNIV
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In order to discover new LSD1 / HDACs dual-target inhibitors, explore the synthesis of a class of diarylethene compounds containing hydroxamic acid groups, and verify its LSD1, HDACs dual inhibitory activity and in vitro anti-tumor activity are the starting point of this application. So far, there are no reports on the synthesis, LSD1 / HDACs inhibitory activity and antitumor activity of this kind of compound

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hydroxamic acid group-containing diarylethene LSD1/HDACs double-target inhibitors as well as preparation method and application thereof
  • Hydroxamic acid group-containing diarylethene LSD1/HDACs double-target inhibitors as well as preparation method and application thereof
  • Hydroxamic acid group-containing diarylethene LSD1/HDACs double-target inhibitors as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Embodiment 1 (E)-4-(2-(2-bromo-pyridin-4-yl) alkenyl) synthetic of methyl benzoate (I-3a)

[0023]

[0024] Add compound I-1a (376mg, 2.0mmol) and I-2a (601.1mg, 2.1mmo) to a 50ml two-necked flask, dissolve with 10ml of anhydrous DMF, add t-BuOK (673.3mg, 6.0mmol) under ice-cooling After the addition was completed, the reaction was stirred at room temperature for 0.5 hours, and then the reaction system was slowly added to ice water (50 mL), and a solid was precipitated. The solid was collected by suction filtration, separated and purified by silica gel column chromatography (petroleum ether: ethyl acetate = 5:1) to obtain 396.4 mg of compound I-3a, a white solid, yield: 62.3%, Mp: 106-107°C. 1 H NMR (400 MHz, CDCl 3 )δ8.36(d,1H,J=5.2Hz),8.08(d,2H,J=8.4Hz),7.60-7.57(m,3H),7.34-7.29(m,2H),7.04(d,1H ,J=16.4Hz),3.95(s,3H). 13 CNMR (101MHz, CDCl 3 )δ166.57, 150.44, 146.96, 143.04, 139.95, 133.46, 130.39, 130.20, 127.05, 126.87, 125.16, 120.09, 52.27. HRMS (ESI) calcd ...

Embodiment 2

[0025] Synthesis of embodiment 2 (E)-4-(2-(2-bromo-pyridin-4-yl) alkenyl) methyl benzoate (I-3b)

[0026]

[0027] According to the method of Example 1, compound I-2b (601.1mg, 2.1mmol) was used to replace I-2a to obtain 288.3 mg of target compound I-3b, a white solid, yield: 45.4%, Mp: 73-74°C. 1 H NMR (400MHz, CDCl 3 )δ8.33(d, 1H, J=5.2Hz), 8.21(t, 1H, J=2.0Hz), 8.00(dt, 1H, J 1 =1.2Hz,J2 =8.0Hz),7.70(dt,1H,J 1 =1.6Hz,J 2 =8.0Hz),7.57(s,1H),7.48(t,1H,J=8.0Hz),7.35-7.30(m,2H),7.03(d,1H,J=16.4Hz),3.96(s,3H ).HRMS(ESI)calcd for C 15 h 12 BrNNaO 2 [M+Na] + :339.9944,Found:339.9943.

Embodiment 3

[0028] The synthesis of embodiment 3 (E)-3-(3-bromostyryl) methyl formate (I-3c)

[0029]

[0030] According to the method of Example 1, compound I-1b (370 mg, 2.0 mmol) was used to replace I-1a to obtain 480 mg of target compound I-3c, yield: 75.6%, Mp: 177-178 ° C. 1 H NMR (400MHz, DMSO-d 6 ) δ7.97(d, 2H, J=8.4Hz), 7.89(t, 1H, J=2.0Hz), 7.74(d, 2H, J=8.4Hz), 7.64(dt, 1H, J 1 =1.2Hz,J 2 =8.0Hz),7.51-7.48(m,1H),7.43(d,2H,J=4.0Hz),7.37(t,1H,J=8.0Hz),3.86(s,3H). 13 C NMR (101MHz, DMSO-d 6 )δ166.41, 141.90, 139.66, 131.31, 131.20, 130.09, 129.65, 129.38, 129.04, 127.28, 126.38, 122.76, 52.57. HRMS (ESI) calcd for C 16 h 13 BrNaO 2 [M+Na] + :338.9991,Found:338.9996.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to hydroxamic acid group-containing diarylethene LSD1 / HDACs double-target inhibitors, a preparation method thereof and application thereof in preparation of antitumor drugs, andbelongs to the technical field of medicinal chemistry. The compounds have a general formula shown in the specification, wherein 3-position or 4-position monosubstitution is preferred; R2 is preferablyOH, OCH3, F or H; R3 is preferably selected from H and CH2OH; R4 is preferably selected from H, CH3, F, or OCH3; R5 is preferably selected from H, OH, CH2OH, CH3, F and OCH3; X is N or CH; Y is N orCH. The compounds provided by the invention have relatively strong inhibitory activity on LSD1 and HDAC1 / 6, and have very good selectivity on LSD1, and the in vitro antitumor activity of the multiplecompounds on human colon cancer HCT-116 cell strains and human gastric cancer MGC-803 cell strains is superior to that of commercially available drug SAHA. A basis is provided for research and development of LSD1 / HDACs double-target inhibitor drugs, and the compounds can be used as candidates for further development or lead compounds for development of antitumor treatment drugs.

Description

technical field [0001] The invention specifically relates to a class of diarylethene LSD1 / HDACs dual-target inhibitors containing hydroxamic acid groups, a preparation method thereof and an application in the preparation of antitumor drugs, belonging to the technical field of medicinal chemistry. Background technique [0002] Histone lysine-specific demethylase 1 (LSD1) was first reported by Professor Shi Yang of Harvard University in 2004. It is a flavin adenine dinulcleotide (FAD)-dependent amino oxidase , can specifically remove the mono- and di-methyl groups of histone H3K4. The discovery of LSD1 confirmed the dynamic balance between methylation and demethylation of histones. In addition, LSD1 can also demethylate non-histone proteins such as p53, DNMT1, STAT3, E2F1, MYPT1, ERa, and HIF-1, further regulating the stability and activity of its downstream genes. A large number of studies have shown that the expression of LSD1 in various tumors such as lymphoma, acute myel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D213/61C07D213/55C07D213/56C07C69/84C07C259/10C07C67/343A61P35/00
CPCC07D213/61C07D213/55C07D213/56C07C69/84C07C259/10A61P35/00
Inventor 段迎超靳林峰关圆圆袁航文郁康陈书慧秦文平张少杰
Owner XINXIANG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com